After the holiday, there is a "surge" of new IPOs, and the enthusiasm for IPO subscriptions is "heating up" again.
```
The National Day holiday has just ended, but the enthusiasm in the capital market remains undiminished. In the first full trading week after the holiday, a cluster of new listings has ignited investors’ enthusiasm once again. Whether it is Aomeisen, which soared on its first day, or the upcoming biotech and hard technology firms, all have injected “fresh water” into the market, sustaining the hot momentum in new stock offerings.
The bustle in the capital market after the holiday is not just a release of short-term sentiment, but also a true reflection of the innovation-driven strategy on the capital side. From intelligent manufacturing to biotech, and then to chip materials, a technological thread in new stock listings is becoming clearly visible.
1. Triple Gains Become the Focus Again
Over the past week, the most eye-catching was undoubtedly the debut of Aomeisen. This enterprise, focusing on intelligent equipment manufacturing, got listed on the Beijing Stock Exchange, quickly becoming a "hot pick" in the post-holiday market.
According to the issuance announcement, Aomeisen's allocation ratio was only 0.0223%, meaning that each successful allotment was “like crossing a single-plank bridge among thousands,” reflecting the strong enthusiasm for new listings in the market.
On its first trading day, Aomeisen's share price soared, with an average increase of 347.50%. The turnover rate that day approached 80%, showing remarkable trading activity. The hard tech background together with solid pricing has made Aomeisen a focal point for capital chasing.
2. Biotech Sector Continues Its Strength
In the coming week, the new stock market is bustling. The listing process of two companies from the biotech sector, Hop Yuan Biotech and BEBT, has attracted market attention as both are listing on the STAR Market. Currently, the biotech industry remains in a structural growth cycle, with innovative drugs and other niche areas continuing to be the focus for capital.
Hop Yuan Biotech is deeply involved in the R&D and production of biological macromolecule drugs and is regarded as an innovation leader in China’s biopharmaceutical field. The company has solid foundations in recombinant protein drugs, having developed various medicines and related research reagents.
During the reporting period, Hop Yuan Biotech’s operating revenue was 13.3997 million yuan, 24.2641 million yuan, and 25.2161 million yuan respectively. Due to high R&D investment and lengthy product approval procedures, the company is not yet profitable.
BEBT, on the other hand, focuses on major diseases such as cancer and autoimmune diseases. With its proprietary technology, it has made a splash in precision medicine, and the funds raised will be used for new drug development. The company is still not profitable, but its innovative product BEBT-908 has already received approval for launch.
3. Leading Silicon Wafer Developer
Another new listing—Xi’an Yicai—will also be open for subscription in the coming week. This company specializes in the R&D, production, and sales of 12-inch silicon wafers, and is one of the few domestic firms capable of mass production of large silicon wafers.
Based on 2024 monthly average shipments and year-end capacity statistics, Xi’an Yicai ranks first in mainland China and sixth globally among 12-inch silicon wafer manufacturers, making it an industry leader.
During the reporting periods, the company’s operating revenue was 1.055 billion yuan, 1.473 billion yuan, and 2.121 billion yuan, with growth rates of 39.62% and 43.99%. Due to upfront R&D investment and high fixed costs, the company has yet to achieve profitability.
As the chip industry chain accelerates its development, the importance of silicon wafers as a key material is becoming increasingly prominent. Under the strategy of scientific self-reliance, the listing of Xi’an Yicai is expected to add another strong player to the STAR Market.
Risk Warning and DisclaimerThe market involves risk. Investment should be made cautiously. This article does not constitute personal investment advice, nor does it take into account the individual investment objectives, financial situation, or specific needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article are appropriate to their own situations. You are solely responsible for any investment decisions made based on this information. ```